Management of Protracted Paroxetine Discontinuation Syndrome
Reinitiation and Tapering Strategy
- Restart paroxetine at a low dose and then taper it very gradually over several months (minimum 2–4 months) to resolve protracted discontinuation symptoms that persisted for two months after abrupt cessation. American Academy of Child and Adolescent Psychiatry recommends this approach. 1
- For paroxetine, employ an especially slow taper—slower than for other selective serotonin‑reuptake inhibitors—because its short half‑life and potent serotonin reuptake inhibition predispose to severe, prolonged discontinuation effects. American Academy of Child and Adolescent Psychiatry and The Lancet Psychiatry advise this precaution. 1, 2, 3
Pharmacology of Paroxetine and Discontinuation Features
- Paroxetine’s short elimination half‑life (~21 h) and strong serotonin‑reuptake inhibition make it one of the SSRIs most likely to cause severe and prolonged discontinuation syndrome. American Academy of Child and Adolescent Psychiatry highlights this risk. 1, 2, 3
- The “wave‑like” pattern of symptoms—where busy periods temporarily lessen anxiety but symptoms recur later—is characteristic of antidepressant discontinuation syndrome. American Academy of Child and Adolescent Psychiatry describes this clinical feature. 1, 2
Symptom Monitoring During Reinitiation
- Clinicians should monitor for the typical discontinuation symptom cluster—anxiety, irritability, dizziness, paresthesias, insomnia, and flu‑like sensations—while the patient is on the tapering schedule. American Academy of Child and Adolescent Psychiatry lists these as key signs to watch. 1, 2